Analysts Conflicted on These Healthcare Names: Genmab (GMAB), CbdMD (YCBD) and SAGE Therapeutics (SAGE)
TipRanksFeb 15 08:03 ET
Optimistic Outlook: Buy Rating Affirmed for CbdMD Amid Growth Initiatives and Strategic Expansion
TipRanksDec 29, 2023 07:46 ET
Maxim Group Initiates Coverage On CbdMD With Buy Rating, Announces Price Target of $3
BenzingaOct 5, 2023 11:39 ET
CbdMD Analyst Ratings
BenzingaOct 5, 2023 11:37 ET
No Data
No Data